Biogen (NASDAQ: BIIB) SMNrx data bodes well for high dose safety, said analyst Robyn Karnauskas of Deutsche Bank.

"New ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE